House Bill 803 would change how North Carolina adds new vaccines to the childhood immunization schedule. Under the bill, the Commission for Public Health could not add a new childhood vaccine unless the vaccine has been approved by the U.S. Food and Drug Administration for at least three years. If a vaccine has been FDA-approved for less than three years, it could still be added only if both the North Carolina Medical Society Board of Directors and the North Carolina Pediatric Society Board of Directors recommend it.
The bill also revises the state immunization statute to clarify that the Commission must confirm FDA approval before requiring a vaccine, and it updates rulemaking language on vaccine schedules, exemptions, administration procedures, fees, and limits on conditions placed on families receiving state-provided vaccines. In addition, it preserves and restates the existing prohibition on requiring COVID-19 vaccination or proof of vaccination for students at public schools, community colleges, UNC institutions, and private colleges or universities receiving state funds, with a narrow exception for certain clinical or training programs tied to CMS-certified facilities.
HB803 would directly amend G.S. 130A-152, narrowing the Commission for Public Health’s discretion to add new childhood immunization requirements by imposing a three-year FDA-approval waiting period, subject to a professional-society exception. It would affect parents, guardians, schools, public health officials, and vaccine policy administrators by limiting when new vaccine mandates can take effect for children in North Carolina. The bill also reinforces the state’s existing COVID-19 vaccine mandate ban for students in most educational settings and makes the new restrictions applicable only to future vaccine requirements adopted on or after the act becomes law.
Based on the bill text and its sponsorship, the measure appears to reflect a cautious or skeptical approach to adding new childhood vaccine requirements, emphasizing a longer track record of FDA approval and professional review before mandates can be imposed. No committee transcript or vote data is available, so there is no recorded debate or roll-call sentiment to assess. The bill was referred to the House Health Committee and then onward in the process, indicating it was still in early committee consideration at the time of the provided record.
The main point of contention is likely the three-year FDA approval requirement, which could be viewed by supporters as a safety and stability safeguard but by opponents as an unnecessary barrier that could delay public-health responses and vaccine access. Another likely dispute is the exception allowing earlier adoption only with recommendations from the North Carolina Medical Society and North Carolina Pediatric Society, which shifts influence toward professional organizations rather than the Commission for Public Health. The bill’s explicit COVID-19 vaccination prohibition for students may also be controversial, especially among public health advocates, educational institutions, and healthcare training programs that may want broader vaccination authority.